Top Tweets for #Podium2Screen
Durable is the word!!!
KEYNOTE 564
At 7 years, 57% of patients on adjuvant pembrolizumab are disease-free vs 45% on placebo, with an OS benefit and no new safety signals. This is the data I want in my adjuvant discussions.
Thanks @DrChoueiri. #ESMO26 #RCC #Podium2Screen @OncoAlert
OncoAlert founding faculty Dr. Toni Choueiri 🇺🇸 of Dana Farber walks us through adjuvant pembrolizumab vs placebo in high-risk ccRCC:
📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
▶️ Watch now 👇
#kidneycancer #RCC #kidneycancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Cisplatin-ineligible MIBC finally has a perioperative regimen with an OS benefit. D + EV: EFS HR 0.51, OS HR 0.58, pCR 45% vs 10%. Watch @tompowles1 walk through VOLGA 👇 #Podium2Screen #ESMO26
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
🚨 #ESMO26 #Podium2Screen KEYNOTE-564
@OncoAlert
When an adjuvant trial still shows both DFS and OS benefit after nearly 7 years, that is the kind of durability that changes confidence in a standard.
@DrChoueiri 🇺🇸 from Dana-Farber walks us through the final analysis of adjuvant pembrolizumab vs placebo after nephrectomy in high-risk clear-cell #RCC:
📊 DFS: HR 0.68
7-year DFS: 57.2% vs 44.6%
📊 OS: HR 0.70
7-year OS: 82.3% vs 76.6%
✅ No new safety signals
🎯 Why this matters: this is no longer just a recurrence-delay story.
The sustained OS benefit confirms that adjuvant pembrolizumab can translate into long-term survival gain in appropriately selected high-risk ccRCC.
For me, the next precision question is:
Can we now identify more accurately who truly needs adjuvant therapy — and who may safely avoid it?
Durable benefit. Mature follow-up. Standard reinforced.
▶️ Watch @DrChoueiri’s breakdown 👇
@tompowles1 @brian_rini @DrDanielHeng @TiansterZhang @HHammersMD @AlbigesL @montypal @apolo_andrea @crisbergerot @nataliagandur
#OncoAlert #ESMO26 #KidneyCancer #ccRCC #AdjuvantTherapy #Immunotherapy #GUOncology
OncoAlert founding faculty Dr. Toni Choueiri 🇺🇸 of Dana Farber walks us through adjuvant pembrolizumab vs placebo in high-risk ccRCC:
📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
▶️ Watch now 👇
#kidneycancer #RCC #kidneycancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
📌 OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
📌 @OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
Early + definitely worth watching!
At #ESMO26, @OncoAlert #Podium2Screen brings XmAb819 straight to our feed: a first-in-class ENPP3×CD3 bispecific showing a 27% ORR in heavily pretreated RCC!
Phase I, so no victory laps yet…but this is exactly the kind of signal worth tracking!🎯
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
From podium to practice, in real time!
@OncoAlert #Podium2Screen brings the final LITESPARK-011 data straight from #ESMO26! And who better to unpack it than @DrDanielHeng ✨
The slide is one thing…but the expert context is the OncoAlert part 😉
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🚨 #ESMO26 #Podium2Screen XmAb819 in advanced #RCC
@OncoAlert
This is exactly the kind of signal that makes you pay attention in heavily pretreated kidney cancer.
@montypal 🇺🇸 presents XmAb819, a first-in-class ENPP3 × CD3 bispecific T-cell engager in ccRCC.
📊 Early efficacy
➡️ ORR 27%
➡️ DCR 68%
➡️ ORR 26% even after prior HIF-2α inhibitor
➡️ 15/16 responders remain on treatment
🎯 Why this matters: after IO, VEGF-targeted therapy and now HIF-2α inhibition, we urgently need mechanisms that are truly different — not just another variation of the same pathway.
XmAb819 opens a new direction: redirecting T cells against ENPP3-expressing tumor cells.
For me, the most interesting question is whether this activity can become durable enough — and safe enough — to establish T-cell engagement as a meaningful new therapeutic pillar in RCC.
Early data, yes. But biologically very interesting.
Excellent presentation by @montypal, with @AlbigesL @MehmetAsimBilen.
@DrChoueiri @tompowles1 @brian_rini @TiansterZhang @HHammersMD @AlbigesL @DrDanielHeng @crisbergerot @neerajaiims @nataliagandur
#OncoAlert #ESMO26 #KidneyCancer #ccRCC #Bispecifics #TCellEngager #GUOncology
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🚨 #ESMO26 #Podium2Screen LITESPARK-011
@OncoAlert
A new post–PD-(L)1 option in advanced #RCC — but the story is more nuanced than PFS alone.
@DanielHengMD 🇨🇦 presents the final phase III analysis of belzutifan + lenvatinib vs cabozantinib:
📊 PFS: 14.8 vs 10.8 mo
HR 0.74
🎯 ORR: 53% vs 40%
⏳ DoR: 22.0 vs 11.9 mo
📈 OS: HR 0.85 — not statistically significant
🎯 Why this matters: belzutifan + lenvatinib delivers deeper and more durable disease control after prior immunotherapy, but without a demonstrated OS advantage.
For me, the clinically interesting question now is not simply whether this is another active post-IO regimen.
It is where it should sit in sequencing — relative to cabozantinib and other increasingly available options — and whether biology can help identify the patients most likely to benefit from HIF-2α + VEGF inhibition.
Excellent breakdown by @DanielHengMD.
@DrChoueiri @tompowles1 @brian_rini @TiansterZhang @HHammersMD @AlbigesL @montypal @apolo_andrea @crisbergerot @nataliagandur
#OncoAlert #KidneyCancer #Belzutifan #Lenvatinib #GUOncology #PrecisionOncology
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🚨 #ESMO26 | #Podium2Screen — LITESPARK-012
@OncoAlert
A useful reminder in advanced #RCC:
Adding more active drugs does not necessarily create a better first-line regimen.
@DrChoueiri presents phase III LITESPARK-012, evaluating whether adding either belzutifan or the CTLA-4 antibody quavonlimab to pembrolizumab + lenvatinib could improve outcomes.
📊 n=1,688
➡️ No improvement in PFS
➡️ No improvement in OS
➡️ No improvement in ORR
➡️ Higher treatment discontinuation in the triplet arms
🎯 Why this matters: negative trials can be highly informative.
They tell us that simply layering another mechanistically attractive agent onto an effective backbone is not enough. Biology, sequencing, toxicity and patient selection still matter.
For me, the message is clear:
pembrolizumab + lenvatinib remains an established 1L standard — and future intensification needs a stronger biological rationale, not just another drug.
Excellent discussion by @DrChoueiri with @tompowles1 @MVossMD @ERPlimackMD @HowardGurney @brian_rini
Pinging @DrDanielHeng @TiansterZhang @HHammersMD @AlbigesL @montypal @apolo_andrea @crisbergerot @neerajaiims @DrYukselUrun @nataliagandur
#OncoAlert #ESMO26 #KidneyCancer #ccRCC #Immunotherapy #Belzutifan #GUOncology
🚨 #ESMO26 #Podium2Screen: LITESPARK-012 in advanced #RCC
Our @OncoAlert founding faculty @DrChoueiri presents
➡️ Adding belzutifan or CTLA-4 blockade (quavonlimab) to pembrolizumab + lenvatinib did NOT improve PFS, OS or ORR (n=1688)
@tompowles1 @MVossMD @ERPlimackMD
@HowardGurney @brian_rini
➡️ Higher discontinuation rates in the triplet arms
Pembro + lenvatinib remains a 1L standard 👇
#KidneyCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
🚨 #ESMO26 #Podium2Screen: LITESPARK-012 in advanced #RCC
Our @OncoAlert founding faculty @DrChoueiri presents
➡️ Adding belzutifan or CTLA-4 blockade (quavonlimab) to pembrolizumab + lenvatinib did NOT improve PFS, OS or ORR (n=1688)
@tompowles1 @MVossMD @ERPlimackMD
@HowardGurney @brian_rini
➡️ Higher discontinuation rates in the triplet arms
Pembro + lenvatinib remains a 1L standard 👇
#KidneyCancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
📌 An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
This is what makes #Podium2Screen so valuable! 🚀
Bringing the latest data and expert insights directly from the #ESMO2026 sessions to the global oncology community in real time.
Great initiative by @OncoAlert! 👏🌍
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
👑 This is why #Podium2Screen works!
Straight from the #ESMO26 Presidential Session, @tompowles1 breaks down VOLGA for @OncoAlert: perioperative durvalumab + EV delivers major EFS and OS gains, with pCR rising to 45%.
And the twist? More wasn’t necessarily better, adding tremelimumab did not improve the story.
Big data + immediate context. That’s the OncoAlert advantage. 🚨
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
@jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
https://t.co/r0hbOX6twj
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
🎬 #Podium2Screen from #ESMO26
@OncoAlert
One of the most interesting things about the evERA biomarker analysis is that the treatment signal seems to hold across very different molecular contexts.
@stolaney1 🇺🇸 from @DanaFarber walks us through the data:
🔹 Giredestrant + everolimus maintained PFS benefit regardless of ctDNA fraction
🔹 Benefit persisted across ESR1 variants, including Y537
🔹 The signal was also preserved in poor-prognosis subgroups such as TP53, GATA3 and RB1
🎯 Why this matters: biomarkers can tell us who has more aggressive biology — but that does not always mean they identify who will or will not benefit from a given treatment.
For me, the key question is whether future analyses can move beyond prognostic stratification and identify a truly predictive signature for endocrine-based combinations after CDK4/6 inhibition.
Excellent discussion by @stolaney1.
@elmayermd @GregoryAVidal @jhaveri_komal @breastoncdoc @DrWGradishar @NaokiNiikura @FavretMD @DraAlfie @hoperugo @BianchiniGP
#OncoAlert #BreastCancer #ESR1 #ctDNA #PrecisionOncology #EndocrineTherapy
🎬 New OncoAlert #Podium2Screen 🎬 from #ESMO26
Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA
@elmayermd, @stolaney1, @GregoryAVidal, @jhaveri_komal, @breastoncdoc, @DrWGradishar, @NaokiNiikura, @FavretMD, @DraAlfie, @hoperugo
🔹 Giredestrant + everolimus kept its PFS benefit regardless of ctDNA fraction
🔹 Benefit held across ESR1 variants, including Y537 (HR 0.35)
🔹 Benefit also held in poor-prognosis subgroups (TP53, GATA3, RB1)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76
🎬 New @OncoAlert #Podium2Screen from #ESMO26 🇪🇸
Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA
🎬 New OncoAlert #Podium2Screen 🎬 from #ESMO26
Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA
@elmayermd, @stolaney1, @GregoryAVidal, @jhaveri_komal, @breastoncdoc, @DrWGradishar, @NaokiNiikura, @FavretMD, @DraAlfie, @hoperugo
🔹 Giredestrant + everolimus kept its PFS benefit regardless of ctDNA fraction
🔹 Benefit held across ESR1 variants, including Y537 (HR 0.35)
🔹 Benefit also held in poor-prognosis subgroups (TP53, GATA3, RB1)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers